Discover how histone H2B monoubiquitination loss in ovarian cancer creates new therapeutic opportunities based on chromatin relaxation.
Discover how groundbreaking research is mapping the molecular signatures of ovarian cancer tumors to develop personalized treatments targeting their blood supply networks.
Discover how blocking both the Ubiquitin-Proteasome System and HDAC6-dependent lysosomal pathway creates synergistic killing of ovarian cancer cells.
Discover how the USP13 gene breakthrough is revolutionizing our understanding and treatment of high-grade serous ovarian cancer.
Exploring how targeting deubiquitinating enzymes (DUBs) associated with the proteasome could revolutionize ovarian cancer treatment by overcoming drug resistance.
Discover how targeting neddylation with MLN4924 could overcome cisplatin resistance in ovarian cancer, offering new hope for patients with recurrent disease.
Discover how dihydroartemisinin (DHA), derived from ancient antimalarial plants, targets PDGFRα in aggressive ovarian cancer, offering new hope against this lethal disease.